The ASCO Post (@ascopost) 's Twitter Profile
The ASCO Post

@ascopost

News and views from the world of clinical oncology and hematology

ID: 96994334

linkhttp://WWW.ASCOPOST.COM calendar_today15-12-2009 14:48:51

34,34K Tweet

61,61K Followers

4,4K Following

The ASCO Post (@ascopost) 's Twitter Profile Photo
The ASCO Post
@ascopost

8 days ago

Sacituzumab govitecan and pembrolizumab help patients with advanced PD-L1–positive TNBC live longer without cancer progression compared with chemotherapy and pembrolizumab. Sara Tolaney #ASCO25 #BreastCancer ascopost.com/news/may-2025/…